Document Detail

A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery.
MedLine Citation:
PMID:  20864169     Owner:  NLM     Status:  MEDLINE    
Research on quantitative control of targeting effect for the drug delivery system of ligand-conjugated nanoparticles of biodegradable polymers is at the cutting edge in the design of drug delivery device. In this work, we developed a post-conjugation strategy, which makes the ligand conjugation after the preparation of the drug-loaded nanoparticles of two copolymers blend. We synthesized the PLGA-PEG copolymer with PEG functioning as the linker molecule needed for herceptin conjugation. Docetaxel-loaded nanoparticles of the PLGA-PEG/PLGA copolymer blend were prepared by the nanoprecipitation method. Anti-HER2 antibody (heceptin), which targets the breast cancer cells of HER2 receptor overexpression, was conjugated on the drug-loaded PLGA-PEG/PLGA nanoparticles for sustained, controlled and targeted delivery of docetaxel. We demonstrated that the targeting effect can be quantitatively controlled by two ways, i.e. (1) adjusting the copolymer blend ratio of the nanoparticle matrix, which showed within the range of 20% PLGA/PEG in the copolymer blend a linear relation with the ligand density on the nanoparticle surface, and (2) adjusting the herceptin feed molar ratio to NH2 in the linker molecules appearing on the nanoparticle surface, which also showed a linear relation. Compared with the pre-conjugation strategy developed recently in the literature, in which the ligand was firstly conjugated onto the PLGA-PEG copolymer before preparation of the nanoparticles of the PLGA-PEG/PLGA copolymer blend, the post-conjugation strategy provides more efficient use of the ligand and protects its bioactivity in the nanoparticle preparation process, thus resulting in much better performance in drug targeting, which was assessed in vitro with SK-BR-3 breast cancer cells of HER2 receptor overexpression and MCF7 breast cancer cells of HER2 receptors moderate expression.
Yutao Liu; Kai Li; Bin Liu; Si-Shen Feng
Related Documents :
16893619 - Microencapsulation of drugs by electro-hydro-dynamic atomization.
17123919 - Enhancing drug incorporation into tetracycline-loaded chitosan microspheres for periodo...
15799539 - Alginate microparticles for polymyxin b peyer's patches uptake: microparticles for anti...
20530409 - Novel local drug delivery system using thermoreversible gel in combination with polymer...
7648659 - Albumin microbubble echo-contrast material as an enhancer for ultrasound accelerated th...
24878199 - Dysoxylum binectariferum bark as a new source of anticancer drug camptothecin: bioactiv...
11861109 - Pharmacokinetic comparison of intravenous carbendazim and remote loaded carbendazim lip...
529019 - Multiple receptor responses: a new concept to describe the relationship between pharmac...
6105019 - Alcohol and benzodiazepines: withdrawal syndromes.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-09-22
Journal Detail:
Title:  Biomaterials     Volume:  31     ISSN:  1878-5905     ISO Abbreviation:  Biomaterials     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-10-18     Completed Date:  2011-01-27     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  8100316     Medline TA:  Biomaterials     Country:  England    
Other Details:
Languages:  eng     Pagination:  9145-55     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Ltd. All rights reserved.
Department of Chemical & Biomolecular Engineering; National University of Singapore, 4 Engineering Drive 4, Singapore.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / administration & dosage,  adverse effects,  chemistry
Antibodies, Monoclonal, Humanized
Biocompatible Materials / administration & dosage,  adverse effects,  chemistry
Cell Line, Tumor
Cell Survival / drug effects
Drug Carriers / administration & dosage,  adverse effects,  chemistry*
Microscopy, Confocal
Nanomedicine / methods
Nanoparticles / administration & dosage,  adverse effects,  chemistry*
Nanotechnology / methods
Neoplasms / drug therapy
Polymers / administration & dosage,  adverse effects,  chemistry*
Taxoids / administration & dosage,  chemistry,  therapeutic use
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Biocompatible Materials; 0/Drug Carriers; 0/Polymers; 0/Taxoids; 15H5577CQD/docetaxel; P188ANX8CK/trastuzumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Acute phase proteins as biomarkers for predicting the exposure and toxicity of nanomaterials.
Next Document:  Bioelectrochemical control of neural cell development on conducting polymers.